NCT06345300 2024-04-03
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
Clinical Trials
13 trialsNCT06282120 2024-02-28
Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Unknown
NCT04617457 2024-01-12
HOLIPANC
University of Cologne
Phase 2 Unknown
NCT05363007 2023-10-16
SINAI
National Taiwan University Hospital
Phase 2 Unknown
NCT03487016 2022-09-08
FOOTPATH
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT02013336 2022-03-31
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
South Plains Oncology Consortium
Phase 1 Unknown
NCT03554707 2022-02-08
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
Phase EARLY_PHASE1 Unknown
NCT05047991 2021-09-17
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT03528785 2021-08-02
nITRo
Centro Ricerche Cliniche di Verona
Phase 2 Unknown
NCT03703063 2021-01-27
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Benaroya Research Institute
Phase 1 Unknown
NCT03986294 2021-01-15
NAPAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Unknown
NCT04569916 2020-09-30
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT03732508 2018-11-06
SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown